Loading…
Loading…
SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
Chesapeake Utilities Corporation (NYSE: CPK - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to
DOVER, Del., Oct. 1, 2026 /PRNewswire/ -- Chesapeake Utilities Corporation (NYSE: CPK) ("Chesapeake Utilities" or the "Company") today announced that it has established an at-the-market equity offering program (the "ATM Program") to sell shares of its common stock having an aggregate sales price of up to $225,000,000, from time to time through either the Managers (as defined below) or the Forward Sellers (as defined below) (including the shares that may be sold pursuant to forward sale agreements, the "Shares").
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPR Newsw
Bank of America Corp DE acquired a new stake in Chesapeake Utilities Corporation (NYSE: CPK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 50,451 shares of the utilities provider's stock, valued at approximately $6,179,000. Bank of America Corp DE
AbbVie Announces European Commission Approval of RINVOQÂ (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisPR
NextEra Energy Resources to acquire a minority interest in landmark South Florida natural gas infrastructure project. DOVER, Del.
Snam (OTCMKTS:SNMRF - Get Free Report) and Chesapeake Utilities (NYSE: CPK - Get Free Report) are both utilities companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership. Profitability This table compares Snam and Chesapeake Utilities' net